Navigation Links
Taiho Pharmaceutical ansöker om godkännande att tillverka och sälja det nya antitumörpreparatet TAS-102
Date:2/26/2013

TOKYO, 27 februari 2013 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. annonserade den 27 februari att man den 26 februari hade lämnat in en ansökan om godkännande för att tillverka och marknadsföra det nya perorala nukleosida antitumörpreparatet TAS-102 (en kombination av trifluorotymidin (FTD) och tipiracil-hydrochloride (TPI) ), till den japanska myndigheten för hälsovård, arbete och välfärd. Taiho Pharmaceutical söker godkännande av TAS-102 för indikationen icke-resektabel, avancerad, återkommande kolorektal cancer.

Ansökan om godkännande är baserad på resultaten från en klinisk fas II-studie (Studie 10040030) som genomförts vid 20 vårdinrättningar i hela Japan. Den var en randomiserad, dubbelblind jämförande studie mellan TAS-102 och placebo med 172 patienter med icke resektabel, avancerad, återkommande kolorektal cancer som var refraktär mot standardcytostatikabehandlingen som består av minst två behandlingsregimer innehållande fluoropyrimidin, irinotekan eller oxaliplatin. Resultaten visade att den grupp som fick TAS-102 hade en längre total överlevnad (medianvärde för total överlevnad: 9,0 månader gentemot 6,6 månader) och en signifikant minskad mortalitetsrisk (HR: 0,56, p=0,0011). Den vanligaste rapporterade läkemedelsbiverkningen med en CTCAE-grad på 3 eller högre var neutropeni. Förekomsten av diarré, trötthet, yrsel och andra biverkningar av grad 3 eller högre översteg ej 10 %. Taiho Pharmaceutical genomför för närvarande en global fas III-studie av TAS-102 hos en liknande patientpopulation med kolorektal cancer (RECOURSE) med den slutgiltiga målsättningen att preparatet ska godkännas och säljas i hela världen.

Taiho P
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
3. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
4. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
5. Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
6. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
7. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
8. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
9. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
10. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
(Date:7/10/2014)... , July 10, 2014   LabStyle ... Management Solution, today announced the appointment of Professor ... member of its Board of Directors. ... and business experience to LabStyle as an entrepreneur, ... legal and corporate governance expert. He currently serves ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Nile Therapeutics,Inc. (Nasdaq: NLTX ), today announced ... failure patient in its Phase IIa, multi-center, open-label,ascending ... candidate,CD-NP, a novel chimeric natriuretic peptide, in development ... The primary objective of the Phase IIa study ...
... 10 Medarex, Inc.,(Nasdaq: MEDX ) today ... in research discovery and antibody development, and the,multiple ... value.,In addition, comprehensive updates on current and future ... were presented by Medarex,s,President and CEO, Howard H. ...
Cached Medicine Technology:Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients 2Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients 3Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 2Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 3Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 4Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 5Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 6
(Date:7/11/2014)... Ohio (PRWEB) July 11, 2014 As ... 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number of ... blood sugar, abdominal issues and even death from the ... , According to the Times report , a ... in 2013 reported by patients was almost 14% of ...
(Date:7/11/2014)... Wash.The largest study of its kind has found ... of advantages over their conventional counterparts, including more ... The study looked at an unprecedented 343 peer-reviewed ... organic and conventional plant-based foods, including fruits, vegetables, ... techniques to quantify differences between organic and non-organic ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... from the worldwide scourge of dengue fever was somewhat successful ... only prevented dengue fever in 56 percent of the 10,000 ... protected more than 88 percent of them from severe disease. ... and sometimes death. "This vaccine has already proven to ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
(Date:7/11/2014)... Europe is one of the largest consumers of ... land area. The agricultural sector is a significant user ... of the total water use. The scale and importance ... but far from negligible in most northern ones. , ... of the water use in most countries, while in ...
Breaking Medicine News(10 mins):Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3
... the surgical treatment of retinal hemorrhages or injuries. The purpose ... to the wall of the eye. There is a risk ... at high altitudes, or under nitrous oxide anesthesia. This expansion ... for weeks after the surgical procedure. , In order to ...
... with a FREE Box of Healthy ... Feb. 25 Every four years, Leap Day,gives us an extra ... you to use that extra day -- which is also the ... help people take,a small leap to healthier eating, the makers of ...
... University of Maryland at College Park have discovered that ... with elevated zinc level, at the high end of ... cell growth, up-regulation of growth arrest and DNA damage-induced ... G2/M cell cycle progression. The research, published in the ...
... who are highly anxious about their skin condition say they ... to new research at the University of Bath (UK). , ... 50 young to middle-aged adults recruited from a national acne ... less likely to participate in sport or exercise, acne sufferers ...
... with Accumulator(R) Variable ... Annuity, ... in retirement, AXA Equitable Life,Insurance Company is offering a new way to ... company,s top-selling,Accumulator(R) variable annuity provides for a minimum 200% benefit base,guarantee if ...
... continues to add,new companies to their customer ... licenses. In the last year, Billian,s HealthDATA ... to provide their,customers, with meticulously researched, cutting-edge ... current information to guide informed,decisions about the ...
Cached Medicine News:Health News:'Free For All' on Leap Day to Get Hearts Pumping! 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 3Health News:Acne may prevent people from participating in sport and exercise, says research 2Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 2Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 3Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 4Health News:Billian's HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence 2Health News:Billian's HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence 3
... Access ...unlike any trocar system you've ever ... actually four systems in one designed ... adaptive to all of your needs., ... or dilating tip styles, OnePort™ can effectively ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
... FPK01 Thoracic Trocar Pak contains: ... flexible sleeves and (1) 12mm ... ,FPK02 Thoracic Trocar Pak contains: ... flexible sleeves., ,FPK03 Thoracic ...
... The FLEXIPATH Flexible Surgical ... solid or mechanical obturator and ... designed to prevent puncture or ... flexible sleeve has securing holes ...
Medicine Products: